The purpose of the study is to evaluate an investigational medication to treat chronic persistent asthma. The research is being conducted at up to 22 clinical research sites in the US and is open to both men and women ages 18 to 70 years old. Participants in the study will have a number of visits to a research site over a 10-month period. All study-related care and medication is provided to qualified participants at no cost: this includes all visits, examinations and laboratory work.

Condition	Treatment or Intervention	Phase
Asthma	Drug: Daclizumab	Phase II

Further Study Details: 

Expected Total Enrollment:  120

Ages Eligible for Study:  18 Years   -   70 Years,  Genders Eligible for Study:  Both

Criteria

Inclusion Criteria:

• History of asthma for 6 or more months
• History of chronic persistent asthma requiring daily high dose inhaled corticosteroid for 3 or more months prior to enrollment

Exclusion Criteria:

• Patients with 10 or more pack years of smoking history or smoking within 12 months of study enrollment
• No significant disease other than asthma

California
      Bensch Research Associates, Stockton,  California,  95207,  United States
      Southern California Research, Mission Viejo,  California,  92691,  United States
      Institute of Health Care Assessment, Inc., San Diego,  California,  92120,  United States
      Medical Research Associates, Long Beach,  California,  90806,  United States
Colorado
      National Jewish Medical and Research Center, Denver,  Colorado,  80206,  United States
      Clinical Reserch Centers of Colorado, Denver,  Colorado,  80230,  United States
Florida
      Florida Center for Allergy and Asthma Reserch, Miami,  Florida,  33176,  United States
Georgia
      Rx Research, Woodstock,  Georgia,  30188,  United States
Illinois
      ICSL Clinical Studies, Bloomington,  Illinois,  61704,  United States
      Asthma and Allergy Center of Chicago, S.C., River Forest,  Illinois,  60305,  United States
Massachusetts
      New England Clinical Studies, North Dartmouth,  Massachusetts,  02747,  United States
Minnesota
      Clinical Research Institute, Minneapolis,  Minnesota,  55402,  United States
New Jersey
      Princeton Center for Clinical Research, Princeton,  New Jersey,  08540,  United States
Oregon
      Allergy, Asthma, and Dermatology Research Center, LLC, Lake Oswego,  Oregon,  97035,  United States
Pennsylvania
      Valley Clinical Research Center, Easton,  Pennsylvania,  18045,  United States
Texas
      Pharmaceutical Research and Consulting, Inc., Dallas,  Texas,  75231,  United States
Wisconsin
      University of Wisconsin Medical School, Madison,  Wisconsin,  53792,  United States
      Allergy and Respiratory Care Center, Milwaukee,  Wisconsin,  53209,  United States

Study ID Numbers:  DAC-1003
Record last reviewed:  October 2003
Last Updated:  October 13, 2004
Record first received:  December 19, 2001
ClinicalTrials.gov Identifier:  NCT00028288
Health Authority: United States: Food and Drug Administration
ClinicalTrials.gov processed this record on 2005-04-08